Esperion Therapeutics, Inc.

NasdaqGM:ESPR 株式レポート

時価総額：US$819.5m

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Esperion Therapeutics 過去の業績

過去 基準チェック /06

Esperion Therapeuticsは29.7%の年平均成長率で業績を伸ばしているが、Pharmaceuticals業界はgrowingで10.7%毎年増加している。売上は成長しており、年平均34.1%の割合である。

主要情報

29.66%

収益成長率

60.52%

EPS成長率

Pharmaceuticals 業界の成長5.95%
収益成長率34.06%
株主資本利益率n/a
ネット・マージン-1.77%
前回の決算情報31 Mar 2026

最近の業績更新

Recent updates

ナラティブ更新 • Jun 22

ESPR: Downgrades And Pending ArchiMed Deal Will Shape Balanced Forward Outlook

Esperion Therapeutics' updated analyst price target has shifted from about $6.50 to roughly $3.20, as analysts point to revised assumptions for revenue growth, profit margins, and future P/E multiples following a recent wave of downgrades. Analyst Commentary Recent Street research on Esperion Therapeutics clusters around a series of downgrades, with analysts reassessing how the company executes on its growth plans and what that could mean for valuation.
ナラティブ更新 • Jun 04

ESPR: Vision 2040 Execution And Corstasis Integration Will Offset Recent Downgrades

Esperion Therapeutics' updated analyst price target holds at $3.16 per share, as analysts weigh a higher discount rate and softer revenue growth assumptions against slightly better profit margin expectations and a modestly lower future P/E, all set against recent downgrades and an earlier move by Citizens to raise its target to $5 from $4 on continued execution of the Vision 2040 plan. Analyst Commentary Recent Street research on Esperion has shifted in a clearly more cautious direction, with several bearish analysts moving to less constructive ratings even as the average price target holds near US$3.16 per share.
ナラティブ更新 • May 19

ESPR: Vision 2040 Plans And Acquisition Are Weighed Against Downgrade Risks

Esperion Therapeutics' updated analyst price target has moved from about $15.92 to $3.28 as analysts factor in a series of recent downgrades alongside mixed sentiment around execution on longer term plans and pipeline expansion. Analyst Commentary Recent research has been dominated by downgrades, but there are still a few points that bullish analysts highlight when they look at Esperion Therapeutics and its current valuation.
ナラティブ更新 • May 04

ESPR: Vision 2040 And Corstasis Deal Will Balance Downgrade Concerns

Narrative Update on Esperion Therapeutics The updated analyst price target for Esperion Therapeutics has moved closer to recent Street views, rising from a fair value estimate of $1.78 to $3.16. Analysts are weighing recent downgrades against research that cites consistent Q4 results, progress on the Vision 2040 plan, and pipeline expansion, including the Corstasis Therapeutics acquisition and ESP-2001 advancement.
ナラティブ更新 • Apr 20

ESPR: Vision 2040 Progress Will Likely Mask Corstasis Execution Risk

Analysts recently lifted their price target on Esperion Therapeutics to $5 from $4, citing Q4 results that aligned with earlier guidance and continued progress on the Vision 2040 plan, including the Corstasis Therapeutics acquisition and advancement of ESP-2001. Analyst Commentary Recent commentary around Esperion focuses on how the updated US$5 price target lines up with the company’s execution on its Vision 2040 plan.
ナラティブ更新 • Apr 06

ESPR: Vision 2040 And Corstasis Deal Will Likely Expose Execution Risks

Analysts raised their price target on Esperion Therapeutics to $5 from $4, citing the company's Q4 results, continued execution of its Vision 2040 plans, the acquisition of Corstasis Therapeutics, and progress with ESP-2001 as key reasons for the update. Analyst Commentary The latest research update highlights that the higher US$5 price target reflects Q4 results that were in line with January guidance, along with continued execution of the Vision 2040 plans.
ナラティブ更新 • Mar 23

ESPR: Vision 2040 Execution And ESP-2001 Progress Will Drive Future Upside

Narrative Update Overview Analysts have lifted their price target on Esperion Therapeutics to $5, up from $4, citing continued execution on Vision 2040, the Corstasis Therapeutics acquisition, and progress with ESP-2001 as key drivers behind the updated valuation inputs. These inputs include a higher fair value estimate and adjusted discount rate and P/E assumptions.
ナラティブ更新 • Mar 09

ESPR: Patent Litigation Outcomes Will Likely Expose Weak Profitability Execution Risks

Analysts have revised their price target for Esperion Therapeutics to align with updated assumptions that keep fair value steady at about $1.78 per share. This reflects higher modeled revenue growth, balanced by lower projected profit margins and a slightly reduced future P/E multiple.
ナラティブ更新 • Feb 22

ESPR: Overweight Rating Will Likely Conceal Risk Around Patent And Profitability Execution

Analysts have adjusted their price target on Esperion Therapeutics to $9, reflecting updated assumptions for revenue growth, profit margin, and forward P/E. This change is supported by recent Street research highlighting the new coverage and target level.
ナラティブ更新 • Feb 08

ESPR: Overweight Rating Will Likely Mask Execution Risk Around Acquisition Strategy

Analysts have raised their price target for Esperion Therapeutics to about US$1.78 from roughly US$1.72, citing updated assumptions around revenue growth, profit margins, discount rate, and future P/E. These changes reflect the recent US$9 initiation from Piper Sandler as part of a broader reassessment of the stock's earnings power and risk profile.
ナラティブ更新 • Jan 24

ESPR: Overweight Rating And Accretive Deal Hunt Will Support Bullish Sentiment

Analysts have nudged their price target for Esperion Therapeutics slightly higher to around US$6.50, citing updated assumptions for revenue growth, profit margin and future P/E that are generally consistent with recent Street research, including the new US$9 target from Piper Sandler. Analyst Commentary Analysts are using the new US$9 reference point to frame both the upside case and the key execution questions around Esperion Therapeutics, with the latest work focusing on how current assumptions for revenue, profit margin and future P/E might play out over time.
ナラティブ更新 • Jan 07

ESPR: Overweight Rating Will Likely Obscure Persistent Execution And Profitability Risks

Narrative Update on Esperion Therapeutics Analysts have lifted their price target on Esperion Therapeutics to US$9, citing updated assumptions for revenue growth, profitability, and future P/E that reflect a more constructive view of the company’s earnings potential. Analyst Commentary Recent coverage highlights a more constructive stance on Esperion Therapeutics, with a US$9 price target used as a reference point for what the business might be worth if current assumptions on revenue and earnings play out as expected.
ナラティブ更新 • Dec 23

ESPR: Rising Street Optimism Will Likely Mask Lingering Execution Risks

Analysts have raised their price target on Esperion Therapeutics to $9.00 from $7.00, reflecting increased confidence in the stock's valuation despite moderating long term growth and margin assumptions. Analyst Commentary Recent Street research has reflected a cautiously optimistic stance toward Esperion Therapeutics, with new coverage and revised price targets coalescing around the $9 level.
ナラティブ更新 • Dec 09

ESPR: Rising Overweight Ratings Will Support Bullish Sentiment Toward Shares

Analysts have nudged their price target for Esperion Therapeutics higher to approximately $6.50 per share from about $6.15, citing supportive Street research, including recent Overweight initiations and target increases. These changes reflect confidence in the company’s longer term earnings multiple despite slightly tempered growth and margin assumptions.
ナラティブ更新 • Nov 25

ESPR: Overweight Ratings And Positive Developments Will Strengthen Bullish Outlook For Shares

Analysts have raised their price target for Esperion Therapeutics from $7 to $9 per share. This reflects improved expectations for the company's revenue growth and fair value based on recent positive coverage and outlook updates.
ナラティブ更新 • Nov 09

ESPR: Price Target Increase Will Drive Renewed Confidence In Future Performance

Analysts have raised their price target for Esperion Therapeutics from $7 to $9, citing improved growth and profitability expectations. Analyst Commentary Bullish Takeaways Bullish analysts have increased their price targets, reflecting growing confidence in the company's outlook and execution capabilities.
Seeking Alpha • Sep 09

Esperion: A Mixture Of Opportunity And Risk: Why I Would Hold For Now

Summary Esperion's stock surged over 30% this month after Q2 results beat expectations, driven by strong U.S. sales and global partnerships. The company benefits from high-margin collaboration revenues and expanding international milestones but faces heavy debt and declining cash reserves. Patent settlements protect U.S. exclusivity through 2040, yet ongoing litigation and financial strain add significant risk to the investment thesis. Given the mix of opportunity and risk, I assign a Hold rating until Esperion demonstrates consistent profitability and improved financial stability. Read the full article on Seeking Alpha
ナラティブ更新 • Aug 06

Rising Digital Adoption And Global Partnerships Will Shape Future Markets

Esperion Therapeutics' consensus price target has increased as analysts now assign a higher future P/E despite a decline in net profit margin, resulting in the APT rising from $5.79 to $6.50. What's in the News Esperion Therapeutics was dropped from the S&P Pharmaceuticals Select Industry Index.
User avatar
新しいナラティブ • May 04

US FDA Approvals And Global Expansion Will Shape Future Markets

International expansion and strategic partnerships are anticipated to significantly boost global sales and royalty revenues over time.
Seeking Alpha • Feb 22

Esperion Therapeutics: Little Upside Potential In Their Earlier Generation Drug

Summary Esperion Therapeutics has two approved LDL-C lowering therapies, Nexletol and Nexlizet, but lacks a strong pipeline for future growth. Recent label expansions for Nexletol and Nexlizet have broadened their indications, but competition from Merck's PCSK9 inhibitor could impact ESPR's market position. Financially, Esperion has limited cash runway and faces challenges from more effective and safer LDL-C lowering treatments like PCSK9 inhibitors. Despite trading near 52-week lows, I see little upside in investing in Esperion due to its moderate benefits and lack of a robust pipeline. Read the full article on Seeking Alpha
Seeking Alpha • Dec 08

Will The Long Awaited Breakout For Esperion Therapeutics Hold?

Summary Esperion Therapeutics' stock broke out above a year-long trading range, signaling a potential sustainable breakout if support at $3.40 holds. Despite past skepticism and price fades, recent technical achievements and strategic moves, including global drug submissions, bolster the stock's outlook. The Piper Sandler Conference reinforced Esperion's growth strategy, with CEO Sheldon Koenigand CFO Ben Halladay providing encouraging news on guidance and business performance. Insider ownership remains low, which could impact confidence, but the company's strategic positioning and milestones present a compelling investment case. Read the full article on Seeking Alpha
Seeking Alpha • Nov 13

Esperion Therapeutics: Growth Initiatives Are Paying Off - Buy

Summary I maintain my buy rating on Esperion Therapeutics due to its strong Q3 2024 financial performance, showcasing consistent revenue growth and market adoption. The Company's aggressive commercialization efforts, including market coverage expansion and sales force growth, have significantly boosted retail prescriptions and broadened future revenue streams. International expansion through partnerships with Daiichi Sankyo Europe and Otsuka Pharmaceutical has driven prescription and revenue growth, strengthening ESPR's global presence. Technical analysis indicates bullish momentum with no signs of reversal, supported by positive financials and key growth drivers, making ESPR a buy. Read the full article on Seeking Alpha
Seeking Alpha • Aug 16

Esperion Therapeutics: Strategically Positioned To Grow

Summary Esperion is a pharmaceutical firm whose focus is to treat patients with high low-density lipoprotein cholesterol (LDL-C). I rate it a buy due to strategic initiatives and market potential driving significant growth. Strong revenue growth and margin expansions reflect improving financial performance and market breakthrough. ESPR's unique non-statin medicines address unmet demand, offering a competitive advantage in the large and growing LDL-C-lowering pharmaceutical market. Read the full article on Seeking Alpha
Seeking Alpha • May 20

Buy Esperion Therapeutics Despite An Abiding Skepticism Weighing On The Stock

Summary Esperion Therapeutics secured FDA approval for expanded labels of its flagship drugs and obtained a patent extension. Despite these successes, the stock trades with the weight of an abiding skepticism. The company's Q1 showed accelerating revenue growth, but guidance offered little new information. A lipid lurker marketing campaign shows early top of the funnel success, but there is little data yet to demonstrate bottom funnel performance. Still, with the stock trading at a valuation discount, I continue to buy ESPR in expectation of significant upside once the company shows evidence of exponential growth and healthy profitability. Read the full article on Seeking Alpha

収支内訳

Esperion Therapeutics の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。

収益と収入の歴史

NasdaqGM:ESPR 収益、費用、利益 ( )USD Millions
日付収益収益G+A経費研究開発費
31 Mar 26418-71660
31 Dec 25403-231660
30 Sep 25304-1061610
30 Jun 25268-1041590
31 Mar 25260-1531640
31 Dec 24332-521630
30 Sep 24295-871720
30 Jun 24278-981650
31 Mar 24230-871550
31 Dec 23116-2091430
30 Sep 23103-2081210
30 Jun 2388-2221130
31 Mar 2381-2391090
31 Dec 2275-2341090
30 Sep 2272-2431230
30 Jun 2267-2581240
31 Mar 2289-2351540
31 Dec 2178-2691720
30 Sep 2173-3081950
30 Jun 2162-3252180
31 Mar 21234-1562060
31 Dec 20228-1442000
30 Sep 20219-1011600
30 Jun 20216-841290
31 Mar 205-263950
31 Dec 19148-97660
30 Sep 19147-95550
30 Jun 19146-77460
31 Mar 19145-68390
31 Dec 180-202330
30 Sep 180-18027-114
30 Jun 180-17524-74
31 Mar 180-17322-36
31 Dec 170-167210
30 Sep 170-15821139
30 Jun 170-13019112
31 Mar 170-1011884
31 Dec 160-75180
30 Sep 160-591941
30 Jun 160-552135
31 Mar 160-532132
31 Dec 150-502030

質の高い収益: ESPRは現在利益が出ていません。

利益率の向上: ESPRは現在利益が出ていません。

フリー・キャッシュフローと収益の比較

過去の収益成長分析

収益動向: ESPRは利益を出していないが、過去 5 年間で年間29.7%の割合で損失を削減してきた。

成長の加速: ESPRの過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。

収益対業界: ESPRは利益が出ていないため、過去 1 年間の収益成長をPharmaceuticals業界 ( -6% ) と比較することは困難です。

株主資本利益率

高いROE: ESPRの負債は資産を上回っているため、自己資本利益率を計算することは困難です。

総資産利益率

使用総資本利益率

過去の好業績企業の発掘

7D

1Y

7D

1Y

7D

1Y

企業分析と財務データの現状

データ最終更新日（UTC時間）
企業分析2026/07/14 06:45
終値2026/07/10 00:00
収益2026/03/31
年間収益2025/12/31

データソース

企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。

パッケージデータタイムフレーム米国ソース例
会社財務10年
  • 損益計算書
  • キャッシュ・フロー計算書
  • 貸借対照表
アナリストのコンセンサス予想+プラス3年
  • 予想財務
  • アナリストの目標株価
市場価格30年
  • 株価
  • 配当、分割、措置
所有権10年
  • トップ株主
  • インサイダー取引
マネジメント10年
  • リーダーシップ・チーム
  • 取締役会
主な進展10年
  • 会社からのお知らせ

* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。

特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。

分析モデルとスノーフレーク

このレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。

シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。

業界およびセクターの指標

私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。

アナリスト筋

Esperion Therapeutics, Inc. 5 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。16

アナリスト機関
Jason ZemanskyBofA Global Research
Kristen KluskaCantor Fitzgerald & Co.
Jason ButlerCitizens JMP Securities, LLC